Pharmaceutical - AstraZeneca, Cardio-vascular

Filter

Popular Filters

1 to 25 of 41 results

Brilinta preferred over clopidogrel in latest AHA/ACC guideline

Brilinta preferred over clopidogrel in latest AHA/ACC guideline

06-10-2014

Anglo-Swedish pharma major AstraZeneca today confirmed that the American Heart Association (AHA) and…

AstraZenecaBrilintaCardio-vascularClopidogrelDaiichi SankyoEli LillyPharmaceuticalprasugrelRegulationSanofiticagrelorUSA

AstraZeneca highlights flexibility of Brilinta/Brilique at ESC

AstraZeneca highlights flexibility of Brilinta/Brilique at ESC

01-09-2014

Anglo-Swedish pharma major AstraZeneca today announced the results of the Phase IV ATLANTIC study, which…

AstraZenecaBrilintaBriliqueCardio-vascularCirculatory systemMedicinePersistent and total coronary occlusionPharmaceuticalResearchST segment elevation myocardial infarctionStroke

Cardiovascular disease has already cost six EU countries over $100 billion in 2014 alone

Cardiovascular disease has already cost six EU countries over $100 billion in 2014 alone

28-08-2014

Research by Anglo-Swedish drug major AstraZeneca into the cost burden of cardiovascular disease has shown…

AstraZenecaCardio-vascularEconomy of the European UnionEuropePharmaceuticalResearch

US DoJ closes investigation into AstraZeneca’s PLATO trial for Brilinta

US DoJ closes investigation into AstraZeneca’s PLATO trial for Brilinta

19-08-2014

Anglo-Swedish drug major AstraZeneca has received confirmation from the US Department of Justice that…

AstraZenecaBrilintaBrilintaCardio-vascularLegalPharmaceuticalUKUSA

AstraZeneca in research accord with Max Planck Institute

AstraZeneca in research accord with Max Planck Institute

08-07-2014

Anglo-Swedish pharma major AstraZeneca has entered an agreement with the Max Planck Institute of Molecular…

AstraZenecaCardio-vascularMetabolicsPharmaceuticalResearch

AstraZeneca stresses confidence in independence, highlighting strong R&D pipeline

15-05-2014

Anglo-Swedish pharma major AstraZeneca, the subject of the controversial takeover attempt by Pfizer,…

AstraZenecaCardio-vascularMergers & AcquisitionsMetabolicsOncologyPharmaceuticalResearchRespiratory and Pulmonary

Ligand signs dyslipidemia related diseases accord with AstraZeneca unit

14-05-2014

US drugmaker Ligand Pharmaceuticals has entered into a licensing agreement and research collaboration…

AstraZenecaCardio-vascularLicensingLigand PharmaceuticalsOmthera PharmaceuticalsPharmaceuticalResearch

US FDA approval for AstraZeneca’s Epanova

US FDA approval for AstraZeneca’s Epanova

06-05-2014

There was good news today for Anglo-Swedish drug major AstraZeneca, as the US Food and Drug Administration…

AstraZenecaCardio-vascularEpanovaLovazaPharmaceuticalRegulationUSAVascepa

AstraZeneca signs deals for antibiotic and cardiovascular research

AstraZeneca signs deals for antibiotic and cardiovascular research

28-01-2014

Anglo-Swedish drug major AstraZeneca has entered into further collaborations to expand its research base,…

Antibiotics and Infectious diseasesAstraZenecaCardio-vascularFOB SynthesisLicensingPharmaceuticalResearch

AstraZeneca and Shionogi settle Crestor arbitration

AstraZeneca and Shionogi settle Crestor arbitration

26-12-2013

Anglo-Swedish drug major AstraZeneca revealed yesterday (December 26) the full resolution of arbitration…

Asia-PacificAstraZenecaCardio-vascularCrestorGlobalLicensingPharmaceuticalShionogi

Atherothrombotic diseases market to grow to $47 billion in 2022

Atherothrombotic diseases market to grow to $47 billion in 2022

23-12-2013

The launch of numerous add-on therapies in the atherothrombotic diseases market (incorporating pharmacotherapies…

AstraZenecaBayerBrilintaCardio-vascularEli LillyevacetrapibGlobalMarkets & MarketingPharmaceuticalXarelto

Modest growth forecast for global CD market

02-12-2013

The global market for cardiovascular disease - comprised of heart failure, myocardial infarction and…

AstraZenecaAZD6140BAY81-8781BayerCardio-vascularLCZ696Markets & MarketingNovartisPharmaceuticalPricingserelaxin

AstraZeneca initiates two additional global studies with Brilinta

AstraZeneca initiates two additional global studies with Brilinta

14-11-2013

Anglo-Swedish drug major AstraZeneca plans to conduct two new clinical studies as part of PARTHENON,…

AstraZenecaBrilintaCardio-vascularPharmaceuticalResearch

New ACC and AHA guidelines could increase sales of statins

New ACC and AHA guidelines could increase sales of statins

13-11-2013

New clinical guidelines have been published for the treatment of cholesterol in people at high risk of…

AbbVieAstraZenecaCardio-vascularCrestorHealthcareLipitorMerck & CoNorth AmericaPfizerPharmaceuticalTricorUSAZetia

AstraZeneca “cooperating” with US DoJ inquiry into Brilinta trial

AstraZeneca “cooperating” with US DoJ inquiry into Brilinta trial

01-11-2013

AstraZeneca said it is cooperating with the US Department of Justice after an investigation has been…

AstraZenecaBrilintaCardio-vascularEuropeLegalPharmaceutical

US FDA accepts Epanova NDA filing

18-09-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) today announced that the US Food and Drug Administration…

AstraZenecaCardio-vascularEpanovaNorth AmericaOmthera PharmaceuticalsPharmaceuticalRegulation

Onglyza meets primary safety endpoint in SAVOR CV outcomes trial

02-09-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb (NYSE: MBY) today…

AstraZenecaBristol-Myers SquibbCardio-vascularDermatologicalsOnglyzaPharmaceuticalResearch

AstraZeneca target Omthera files for US approval of Epanova

09-07-2013

Emerging US specialty pharmaceutical company Omthera Pharmaceuticals (Nasdaq: OMTH) today (July 9) announced…

AstraZenecaCardio-vascularCrestorEpanovaOmthera PharmaceuticalsPharmaceutical

New Zealand to fund AstraZeneca's Brilinta for acute coronary syndromes

10-06-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, says it has reached an agreement with the local…

Asia-PacificAstraZenecaBrilintaCardio-vascularPharmaceuticalPricingRegulation

AstraZeneca to buy Omthera in up to $443 million deal

28-05-2013

Anglo-Swedish drug major AstraZeneca's (LSE: AZN) new chief executive Pascal Soriot is making another…

AstraZenecaCardio-vascularEpanovaMergers & AcquisitionsOmthera PharmaceuticalsPharmaceutical

AstraZeneca acquires AlphaCore; Merck Serono links with BioMed X

03-04-2013

In line with its stated policy of targeted acquisitions, Anglo-Swedish drug major AstraZeneca (LSE: AZN)…

AlphaCore PharmaAstraZenecaBiotechnologyCardio-vascularMerck KGaAMerck SeronoMergers & AcquisitionsMetabolicsPharmaceuticalResearch

Proposal to list AstraZeneca's Brilinta in New Zealand

26-03-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to fund the…

Asia-PacificAstraZenecaBrilintaCardio-vascularFinancialHealthcarePharmaceuticalPricingticagrelor

1 to 25 of 41 results

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top